Cleo Diagnostics Narrows Asset Gap as Loss Widens on Lower Revenue

CLEO Diagnostics Ltd ( (AU:COV) ) just unveiled an update.

Cleo Diagnostics reported a wider half-year loss of $1.98 million for the period ended 31 December 2025, a 1.7% increase from the prior corresponding period, as revenue from ordinary activities fell 53.3% to $89,119. The result was partly offset by $1.72 million in Research and Development Tax Incentives, and net tangible assets per share improved to 6.20 cents from 4.26 cents, with no dividends declared.

The company said it continued to invest in U.S. and Australian clinical trials and advanced efforts to patent its licensed technology across key global jurisdictions. This ongoing R&D and intellectual property push underscores a strategy focused on long-term value creation rather than near-term profitability, with implications for shareholders who face continued losses but an improving asset base and potential future commercialisation upside.

The most recent analyst rating on (AU:COV) stock is a Buy with a A$1.26 price target. To see the full list of analyst forecasts on CLEO Diagnostics Ltd stock, see the AU:COV Stock Forecast page.

More about CLEO Diagnostics Ltd

Cleo Diagnostics Limited is a medical diagnostics company focused on developing and commercialising licensed diagnostic technologies. The company is advancing clinical trials in the U.S. and Australia and is working to secure global patent protection for its core technology, positioning itself within the innovative healthcare and biotech sector.

Average Trading Volume: 347,764

Technical Sentiment Signal: Buy

Current Market Cap: A$84.85M

See more insights into COV stock on TipRanks’ Stock Analysis page.